Coya Therapeutics (COYA) Current Deferred Revenue (2023 - 2026)
Coya Therapeutics (COYA) posted Current Deferred Revenue of $1.2 million for Q1 2026, up 3.74% sequentially from $1.2 million in Q4 2025, and up 47.68% YoY from $841414.0 in Q1 2025.
Coya Therapeutics (COYA) Current Deferred Revenue (2023 - 2026) Analysis & Trends
Coya Therapeutics has reported Current Deferred Revenue for 4 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 47.68% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 47.68% YoY) and the FY2025 annual result came in at $1.2 million, up 41.21% from the prior year.
- Current Deferred Revenue improved to $1.2 million in Q1 2026 per COYA's latest filing, from $1.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.2 million in Q1 2026 and troughed at $573089.0 in Q3 2024.
- A 4-year average of $890288.0 and a median of $882499.0 in 2024 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 59.96% in 2025, down 22.15% in 2025.
- Over 4 years, Current Deferred Revenue stood at $923109.0 in 2023, then decreased by 8.11% to $848286.0 in 2024, then soared by 41.21% to $1.2 million in 2025, then grew by 3.74% to $1.2 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.2 million, $1.2 million, and $916712.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.24 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 916,712.00 |
| Jun 30, 2025 | 731,075.00 |
| Mar 31, 2025 | 841,414.00 |
| Dec 31, 2024 | 848,286.00 |
| Sep 30, 2024 | 573,089.00 |
| Jun 30, 2024 | 939,035.00 |
| Mar 31, 2024 | 689,669.00 |
| Dec 31, 2023 | 923,109.00 |